Critical Comparison: enGene (NASDAQ:ENGN) versus Onconetix (NASDAQ:ONCO)

enGene (NASDAQ:ENGN) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of recent ratings for enGene and Onconetix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2	8	4	0	2.14
Onconetix	1	0	0	0	1.00

enGene currently has a consensus target price of $11.05, indicating a potential upside of 505.23%. Given enGene’s stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Onconetix.

Risk & Volatility

enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the S&P 500. Comparatively, Onconetix has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500.

Earnings and Valuation

This table compares enGene and Onconetix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30 million	($2.17)	-0.84
Onconetix	$645,824.00	3.74	-$14.03 million	$248.12	0.00

Onconetix has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

64.2% of enGene shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Comparatively, 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares enGene and Onconetix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Onconetix	-1,575.89%	-91.95%	-53.76%

Summary

enGene beats Onconetix on 8 of the 13 factors compared between the two stocks.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

About Onconetix

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.